

Joseph Unger, PhD

4664 Sunnyside Ave. N • Seattle, WA • 98103 • (206) 518-0744 (cell) • (206) 667-2860 (office)
joeunger@gmail.com

EDUCATION

PhD, HEALTH SERVICES RESEARCH, 2013

Area of Emphasis: Evaluative Sciences and Statistics

University of Washington, Seattle, WA

MS, BIOSTATISTICS, 1993

University of Washington, Seattle, WA

BA, MATHEMATICS, 1990

Pomona College, Claremont, CA

PROFESSIONAL EXPERIENCE

ASSISTANT MEMBER

Public Health Sciences

Fred Hutchinson Cancer Research Center, Seattle, WA

February, 2015 – Present

BIOSTATISTICIAN

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA

June 2013-February, 2015

STAFF SCIENTIST

2005-May 2013

SENIOR STATISTICAL ANALYST

1993-2004

STATISTICAL RESEARCH ASSOCIATE (I-V)

Highlights:

- Primary statistician for two practice-changing trials published in the NEJM (Moore, 2015 and Stiff, 2013; see **Publications**).
- Lead author for a study about income disparities in cancer clinical trials (JCO, 2013; see **Publications**).
 - **Press conference** presenter at ASCO, with coverage by MSN.com and the Chicago Tribune.
- Primary statistician for landmark study on older patient enrollment in clinical trials (**Special Article** in NEJM).
 - **Press conference** presenter at ASCO, with coverage by the New York Times and many others.
- Five plenary scientific session presentations (see **Presentations**), with audiences of 400-500.

Primary responsibilities:

- Coordinating Statistician for the Cancer Control and Prevention Program (January 2005-present)
- Lead statistician for the Cancer Care Delivery and Symptom Control/QoL committees
- Special focus on “Big Data” in cancer research, especially the use of large administrative, registry, and clinical trial databases to evaluate the impact of social, demographic, and clinical characteristics on enrollment, treatment, and disease outcomes
- Co-lead investigator and lead statistician for the innovative project linking SWOG patient records with Medicare claims data
- Currently the lead statistician on 25 studies

PROFESSIONAL ACTIVITIES, HONORS AND AWARDS

Outstanding Student, Doctoral Health Services, University of Washington School of Public Health, 2013

Member, American Society of Clinical Oncology, 2012-present

Manuscript Reviewer: Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Journal of General Internal Medicine, Journal of the Society for Clinical Trials, The Breast, Breast Cancer Research and Treatment, Journal of Thoracic Oncology, Clinical Cancer Research, British Journal of Cancer, and The Oncologist

PUBLICATIONS

Peer Reviewed Articles

1. Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, **Unger JM**, Lew DL, Hansen LH, Meyskens FL, Wade JL, Hershman DL. Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. *J Acupunct Meridian Stud*. 2015 Jun;8(3):152-8. doi: 10.1016/j.jams.2015.03.006. Epub 2015 Apr 23. PMID: 26100070
2. Hershman DL, **Unger JM**, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade III JL, Meyskens FL, Moinpour CM. Randomized Multicenter Placebo-Controlled Trial of Omega-3-Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. *J Clin Oncol*. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4. PMID: 25940724
3. Moore HCF, **Unger JM**, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for Ovarian Protection during Breast Cancer Adjuvant Chemotherapy. *N Engl J Med*. 2015 Mar 5;372(10):923-32. Doi: 10.1056/NEJMoa1413204. PMID: 24738668.
4. Persky DO, Miller TP, **Unger JM**, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-cell lymphoma: SWOG S0313. *Blood*. 2015 Jan 8;125(2):236-41. doi: 10.1182/blood-2014-06-584623. Epub 2014 Nov 13. PMID: 25395425
5. **Unger JM**, Hershman DL, Martin D, Etzioni R, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. *J Natl Cancer Inst*. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb. PMID: 25540245
6. Carson WE, **Unger JM**, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. *Cancer Immunol Res*. 2014 Jul 3. pii: canimm.0052.2014. [Epub ahead of print] PMID: 24994597
7. Friedberg JW, **Unger JM**, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. *British J Haematology*. Epub: 18 Apr 2014.
8. **Unger JM**, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. *J Natl Cancer Inst*. 2014 Mar 1;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13. PMID: 24627276.
9. Stiff PJ, **Unger JM**, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous transplant as consolidation for aggressive Non-Hodgkin's lymphoma. **New England Journal of Medicine**. 2013 Oct 31;369:1681-90.
10. Press OW, **Unger JM***, Rimsza LM, Friedberg JW, Leblanc ML, Czuczman MS, Kaminski M, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher R. A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma based on a Phase III Trial of CHOP-Rituximab vs CHOP + 131Iodine-Tositumomab. *Clin Cancer Res*. 2013 Oct 15. [Epub ahead of print] ***Designated as co-first author**
11. Hershman DL, **Unger JM**, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. *J Clin Oncol*. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.
12. Bernstein SH, Epner E, **Unger JM**, LeBlanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma; SWOG 0213. *Ann Oncol*. 2013 Jun;24(6):1587-93. doi: 10.1093/annonc/mdt070. Epub 2013 Mar 15.
13. Zirpoli GR, Brennan PM, Hong CC, McCann SE, Ciupak G, Davis W, **Unger JM**, Thomas Budd G, Hershman DL, Moore HC, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow JR, Albain KS, Ambrosone CB. Supplement use during an intergroup clinical trial for breast cancer (S0221). *Breast Cancer Res Treat*. 2013 Feb;137(3):903-13. doi: 10.1007/s10549-012-2400-2. Epub 2013 Jan 10.
14. **Unger JM**, Hershman D, Albain KS, Moinpour CM, Petersen J, Burg K, Crowley JJ. Patient Income Level and Cancer Clinical Trial Participation. *Journal of Clinical Oncology*. *J Clin Oncol*. 2013 Feb 10;31(5):536-42.
15. Press OW, **Unger JM**, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial of CHOP Chemotherapy Plus Rituximab Compared to CHOP Chemotherapy Plus ¹³¹Iodine-Tositumomab for Previously Untreated Follicular Non-

Hodgkin's Lymphoma (SWOG S0016). *J Clin Oncol*. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10.

16. Deverka PA, Lavalley DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, BW Ruffner, Watkins J, Veenstra DL, Baker LH, **Unger JM**, Ramsey SD. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. *Journal of Comparative Effectiveness Research*. July 2012, Vol. 1, No. 4, Pages 359-370 , DOI 10.2217/cer.12.36 (doi:10.2217/cer.12.36)
17. Mahadevan D, **Unger JM**, Spier CM, Persky DO, Young F, Leblanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer*. 2013 Jan 15;119(2):371-9. doi: 10.1002/cncr.27733. Epub 2012 Jul 25. PMID: 22833464
18. Stopeck AT, **Unger JM**, Rimsza LM, Leblanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. *Blood*. 2012 Aug 9;120(6):1210-7. Epub 2012 Jun 25. PMID: 22734071
19. Javid SH, **Unger JM**, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara, Jr., PN, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment to breast cancer clinical trials (SWOG S0316). *Oncologist*. 2012;17(9):1180-90. Epub 2012 Jun 20. PMID: 22723506
20. Rimsza LM, **Unger JM**, Tome ME, Leblanc ML. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma. *PLoS One*. 2011;6(8):e22267. Epub 2011 Aug 4.
21. Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, **Unger JM**, Flaherty LE, Sondak VK. A phase 2 trial of complete resection for stage IV melanoma: Results of Southwest Oncology Group Clinical Trial S9430. *Cancer*. 2011 Oct 15;117(20):4740-06. doi: 10.1002/cncr.26111. Epub 2011 Mar 31
22. Stasik CJ, Nitta H, Zhang W, Mosher CH, Cook JR, Tubbs RR, **Unger JM**, Brooks TA, Persky DO, Wilkinson ST, Grogan TM, Rimsza LM. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. *Haematologica*. 2010 Apr;95(4):597-603.
23. Albain KS, **Unger JM**, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *J Natl Cancer Inst*. 2009 Jul 15;101(14):984-92. Epub 2009 Jul 7.
24. Stopeck AT, **Unger JM**, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group study S0108. *Leuk Lymphoma*. 2009 May;50(5):728-35.
25. Hershman DL, **Unger JM**, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology Group Studies S8814/S8897. *J Clin Oncol*. 2009 May 1;27(13):2157-62. Epub 2009 Mar 23.
26. Bernstein SH, **Unger JM**, Leblanc M, Friedberg J, Miller TIP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG-8516 – the Southwest Oncology Group. *J Clin Oncol*. 2009 Jan 1;27(1):114-9. Epub 2008 Dec 1.
27. Rimsza LM, Leblanc ML, **Unger JM**, Miller TP, Grogan TM, DO Persky, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene Expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. *Blood*. 2008 Oct 15;112(8):3425-33. Epub 2008 Jun 10.
28. Persky DO, **Unger JM**, Spier CM, Stea B, Leblanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. *J Clin Oncol*. 2008 May 10;26(14):2258-63. Epub 2008 Apr 14.
29. Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, **Unger JM**, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin's lymphoma: results of a phase III randomized trial by the Southwest Oncology Group (SWOG 9438). *Blood*. 2008 Apr 15;111(8):4048-54. Epub 2008 Feb 6.
30. Ganz PA, Hussey MA, Moinpour CM, **Unger JM**, Hutchins LF, Dakhil SR, Guguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. *J Clin Oncol*. 2008 Mar 10;26(8):1223-30. Epub 2008 Jan 28.
31. Moinpour CM, Hayden KA, **Unger JM**, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol*. 2008 Jan 1;26(1):112-20.

32. Roberts RA, Sabalos CM, Leblanc ML, Martel RR, Frutiger YM, **Unger JM**, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. *Lab Invest*. 2007 Oct;87(10):979-97. Epub 2007 Aug 13.
33. Gotay CC, Moinpour CM, **Unger JM**, Jiang CS, Coleman D, Martino S, Parker BJ, Bearden JD, Dakhil S, Gross HM, Lippman S, Albain KS. Impact of a peer-delivered Telephone Intervention for women experiencing a breast cancer recurrence. *J Clin Oncol*. 2007 May 20;25(15):2093-9.
34. Press OW, **Unger JM**, LeBlanc M, Maloney DG, Miller T, Braziel R, Fisher RF. Five year follow-up of a phase II trial of CHOP chemotherapy followed by Tositumomab/Iodine I 131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group Protocol S9911. *J Clin Oncol*. 2006 Sep 1;24(25):4143-9. Epub 2006 Aug 8.
35. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, **Unger JM**, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Braziel RM, Miller TP. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood*. 2006 Feb 1;107(3):1101-7. Epub 2005 Oct 20.
36. **Unger JM**, Coltman CA Jr, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. *J Clin Oncol*. 2006 Jan 1;24(1):141-4. Epub 2005 Dec 5.
37. Fisher RI, Leblanc M, Press OW, Maloney DG, **Unger JM**, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. *J Clin Oncol*. 2005 Nov 20;23(33):8447-52. Epub 2005 Oct 17.
38. **Unger JM**, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. *Cancer*. 2005 Apr 1;103(7):1375-80.
39. **Unger JM**, LeBlanc M, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. *Urol Oncol*. 2004 Jul-Aug;22(4):362-8.
40. Rimsza LM, Roberts RA, Miller TP, **Unger JM**, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*. 2004 Jun 1;103(11):4251-8. Epub 2004 Feb 19.
41. **Unger JM**, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA 3rd, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA Jr. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial Lecture. *J Clin Oncol*. 2003 Dec 1;21(23 Suppl):246s-252s.
42. Press PW, **Unger JM**, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. *Blood*. 2003 Sep 1;102(5):1606-12. Epub 2003 May 8.
43. Stiff PJ, **Unger JM**, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI; Southwest Oncology Group. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. *Biol Blood Marrow Transplant*. 2003 Aug;9(8):529-39.
44. Tuthill RJ, **Unger JM**, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. *Amer J Clin Pathol*. 2002 Oct;118(4):504-11.
45. Whitehead RP, **Unger JM**, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy – a Southwest Oncology Group study. *Invest New Drugs*. 2002 Feb;20(1):105-11.
46. Sosman JA, **Unger JM**, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA Class I antigen expression on outcome. *J Clin Oncol*. 2002 Apr 15;20(8):2067-75.
47. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, **Unger JM**, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JB, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. *J Clin Oncol*. 2002 Apr 15;20(8):2058-2066.

48. Press PW, LeBlanc M, Richter AS, Grogan TM, **Unger JM**, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. *J Clin Oncol*. 2001 Nov 15;19(22):4238-44.
49. Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C, **Unger J**, Miller TP, Tubbs R, Leith C, Fisher RI, Grogan TM. The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic and clinical features. *Blood*. 2001 Jun 15;97(12):3713-20.
50. Whitehead RP, **Unger JM**, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Evaluation of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy; a Southwest Oncology Group study. *Invest New Drugs*. 2001;19(3):239-243.
51. **Unger JM**, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. *Cancer*. 2001 Mar 15;91(6): 1148-1155.
52. Gaynor ER, **Unger JM**, Miller TP, Grogan TM, White LA Jr, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. *J Clin Oncol*. 2001 Feb 1;19(3):750-755.
53. Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, **Unger JM**, Balcerzak SP, Gaynor ER, Roy V, Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. *J Clin Oncol*. 2000 May; 18(10): 2010-2016.
54. **Special Article, The New England Journal of Medicine:** Hutchins LE, **Unger JM**, Crowley JJ, Coltman CA Jr, Albain KA. Underrepresentation of patients 65 years of age or older in cancer-treatment trials." *N Engl J Med*. 1999 Dec 30;341(27):2061-7.
55. Margolin K, Liu PY, **Unger JM**, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. *J Cancer Res Clin Oncol*. 1999;125(5):292-296.
56. **Unger JM**, van Belle G, Heyman A. Cross-sectional versus longitudinal estimates of cognitive change in nondemented older people: a CERAD study. Consortium to Establish a Registry for Alzheimer's Disease. *J Am Geriatr Soc*. 1999 May;47(5): 559-63.
57. Flaherty LE, **Unger JM**, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. *Am J Clin Oncol*. 1998 Dec;21(6):568-572.
58. Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW 3rd, Fletcher WS, Weiss GR, **Unger JM**, Sondak VK. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. *J Clin Oncol*. 1998 Feb;16(2): 664-669.
59. Whitehead RP, **Unger JM**, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, Sondak VK. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study." *J Immunother*. 1998 Nov;21(6):440-446.
60. Flaherty LE, Liu PY, **Unger J**, Sondak V. Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. *Am J Clin Oncol*. 1997 Dec;20(6):600-604.

Commentaries

61. Hershman DL, **Unger JM**. 'Minority report': how best to analyze clinical trial data to address disparities. *Breast Cancer Res Treat*. 2009 Sep 17. 118:519-521.

Letters

62. Hershman DL, Unger JM. Re: Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Else Thank a Placebo Effect. *J Clin Oncol*. In press.
63. Moore HC, **Unger JM**, Albain KS. Ovarian protection during adjuvant chemotherapy. *N Engl J Med*. 2015 Jun 4;372(23):2269-70. doi: 10.1056/NEJMc1504241. No abstract available. PMID: 26039609
64. Stiff PJ, **Unger JM**, Fisher RI. The role of myeloablation for lymphoma. *N Engl J Med*. 2014 Feb 6;370(6):575-6. doi: 10.1056/NEJMc1314757. No abstract available. PMID: 24499218
65. **Unger JM**, Albain KS. Response re: Racial disparities in cancer survival among randomized clinical trial patients of the Southwest Oncology Group. *J Natl Cancer Inst*. 2010 Feb 24;102(4):1-2. doi: 10.1093/jnci/djp509.

Book Chapters

66. **Unger JM**, Green S, Albain KS. Breast Cancer in Women of African Descent. The Netherlands: Springer; 2006. Chapter 11, Outcome of African American women with breast cancer in cooperative group clinical trials.
67. **Unger JM**, Hutchins LF, Albain KS. Comprehensive Geriatric Oncology. 2nd ed. London and New York: Taylor & Francis; 2004. Chapter 22, Under-representation of elderly patients in cancer clinical trials: Causes and remedial strategies.

PATENTS

Diffuse Large B-Cell Lymphoma Markers and Uses Therefore:

LM Rimsza, ML LeBlanc, JM Unger

- EP Patent 2,297,349, 2011
- US Patent App. 12/996,112
- WO Patent 2,009,149,297

GRANTS

Coltman Fellowship Award (HOPE Foundation) (Unger – PI) [12/1/14-11/30/16]: *The generalizability of clinical trial treatment effects*. Principal investigator.

NCI SWOG Support Grant (HOPE Foundation) (PI- Baker) [7/1/09-12/31/15]: *Organizational infrastructure support to link the SWOG database to Medicare claims*. Co-PI as Statistical Center lead for obtaining the Medicare claims data and coordinating the data linkage.

NCI R01 CA166084-01 (Hershman – PI) [01/12-9/30/16]: *Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors*. Co-PI and study statistician for the project.

NCI R21 CA155973 (Greenlee PI) [9/1/11-8/31/13]: *Feasibility of a weight loss intervention among female cancer survivors in SWOG*. Study statistician.

Susan G. Komen for the Cure®, 2011 Conquer Cancer Foundation of ASCO Improving Cancer Care Grant (ICCG): *Text messaging to reduce early discontinuation of adjuvant hormonal therapy in breast cancer: randomized trial*. Study statistician.

PRESENTATIONS

“Using Medicare claims data to identify late effects following treatment on SWOG clinical trials”

- Seminar, Long Term Effects and Survivorship Affinity Group, Fred Hutchinson Cancer Research Center (June 12, 2015)

“Models to Identify and Support Clinical Trial Participants”

- Invited Speaker, NIH Workshop on the Enrollment and Retention of Participants in NIH-funded Clinical Trials, NIH, Bethesda, MD (July 25, 2014)

“Enhancing the Conduct of Clinical Trials”

- Invited Discussant, Health Services Oral Session, ASCO Conference (June 3, 2013)

“The Diffusion of Docetaxel for Patients Presenting with Metastatic Prostate Cancer”

- Oral Presentation, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting, San Francisco, CA (May 2, 2013)

“The Generalizability of Standard Arm Outcomes for Cancer Patients Treated In and Out of Clinical Trials”

- Oral Presentation, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting, Chicago, IL (October, 2012)
- Plenary Presentation, Southwest Oncology Group Semiannual Meeting, San Francisco, CA (May, 2014)

“Patient Income Level and Cancer Clinical Trial Participation”

- Oral Presentation, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting, San Francisco, CA (April 12, 2012)
- Oral Presentation, ASCO Quality Care Symposium Oral Presentation. Chicago (June 3, 2012)
- Press Briefing, American Society of Clinical Oncology, Chicago (June 2, 2012)
- Oral Presentation, AcademyHealth Conference, Orlando (June, 2012)
- Oral Presentation, NRSA Annual Meeting, Orlando (June, 2012)

“The Cost Effectiveness and Cost Utility of Finasteride for the Prevention of Prostate Cancer”

- Oral Presentation, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting, San Francisco, CA (April, 2011)
- Panel Discussion, University of Washington, Health Services Research Department Annual Research Meeting, Seattle, Washington (June 15, 2011)
- Poster Presentation, AcademyHealth Conference, Seattle, WA (June, 2011)
- Poster Presentation, Biobehavioral Cancer Prevention and Control Annual Symposium (April, 2011)

“The SWOG Clinical Trials Database For Health Outcomes, Disparities, & Comparative Effectiveness Analyses: Past, Present, and Future”

- Oral Presentation, Scientific Session, Health Outcomes and Comparative Effectiveness Committee, Southwest Oncology Group Semiannual Meeting, San Francisco, CA (April 15, 2010)

“Accrual Patterns of the Southwest Oncology Group by Sex, Race/Ethnicity, and Age: Updated and Expanded Analyses”

- Plenary Session, Southwest Oncology Group Semiannual Meeting, Huntington Beach, CA (May, 2004)
- Poster/Discussion, American Society of Clinical Oncology, New Orleans, LA (June 6, 2004)

“The Person-Years Saved Model and Other Methodologies for Assessing the Population Impact of Cancer Prevention Strategies”

- Consensus Conference, Chemoprevention of Prostate Cancer, Reston, VA (March 5, 2004)

“Survival and Toxicity by Sex in SWOG Clinical Trials”

- Scientific Session, Committee on Special Populations, Southwest Oncology Group Semiannual Meeting (October 4, 2003)

“African Americans Have Worse Survival in Hormone-Related Cancers”

- Scientific Session, Committee on Women and Special Populations, Southwest Oncology Group Semiannual Meeting, New Orleans, LA (October 13, 2000)
- Plenary Session, Southwest Oncology Group Semiannual Meeting, San Diego (April 12, 2003)
- Poster/Discussion, American Society of Clinical Oncology, Chicago, Illinois (June 1, 2003)

“Is There a Future for Federally Supported Cancer Clinical Trials?”

- Plenary Session, Southwest Oncology Group Semiannual Meeting, Chicago, IL (October 27, 2001)

“Southwest Oncology Group Accrual by Sex, Race, and Age, Compared to US Population Rates”

- Press Briefing, American Society of Clinical Oncology, Los Angeles, CA (May 18, 1998)
- Poster/Discussion, American Society of Clinical Oncology, Los Angeles, CA (May 18, 1998)
- Plenary Session, Southwest Oncology Group Semiannual Meeting, Atlanta, GA (April 26, 1998)

COMPUTING

- Languages/Software: SAS, R, SQL Plus, STATA, EXCEL, WORD, PowerPoint
- Operating Systems: Windows, UNIX

TEACHING EXPERIENCE

- University of Washington, Biostatistics Department (1992-1993)
 - Position: Graduate Teaching Assistant
- Pomona College, Mathematics Department (1988-1990)
 - Position: Undergraduate Teaching Assistant

REFERENCES

My references are from the following four colleagues and mentors:

- Dr. Diane Martin, epidemiologist, professor emeritus at the University of Washington, and the chair of my dissertation committee (diane.martin@novartis.com)
- Dr. Michael LeBlanc, biostatistician, Director of the SWOG Statistical Center, and Full Member at the Fred Hutchinson Cancer Research Center (mleblanc@fhcrc.org)
- Dr. Dawn Hershman, oncologist, Associate Chair-elect of the SWOG Cancer Control and Prevention Program, and Professor of Medicine at Columbia University (dlh23@cumc.columbia.edu)
- Dr. William Barlow, biostatistician and Professor at the University of Washington (williamb@crab.org)

